SHARES in
The veterinary pharmaceuticals company published a note yesterday to say its outlook for the year is in line with expectations, but that "the balance of trading will be more second half weighted than is typical for
The firm also announced it would release its first-half results on 24 February.
Group net revenue is expected to come in at seven per cent at constant exchange rates for the period.
This was underpinned by an expected European pharmaceutical net revenue growth of 12 per cent at constant exchange rates.
It will be offset by an expected decline of two per cent from its North American sector.
Chief executive
"Trading in
"Our recent acquisitions are integrating well, and we were pleased to reach agreement to acquire Osurnia.
"We therefore remain confident in our prospects for the second half and for the year as a whole."
(c) 2020 City A.M., source